Nivolumab monotherapy yielded 12-month progression-free survival in metastatic anaplastic thyroid cancer
Off-label immunotherapy may help some patients with metastatic anaplastic thyroid cancer
This case report describes a 76-year-old female with metastatic anaplastic thyroid cancer treated with off-label nivolumab monotherapy. The …
A single case report suggests off-label nivolumab helped a 76-year-old woman live longer with metastatic anaplastic thyroid cancer.
Favorable adiposity, statins, vitamin D, dried fruit linked to lower ovarian cancer risk in MR meta-analysis
Genetic study links vitamin D, statins to lower ovarian cancer risk
This systematic review and meta-analysis of Mendelian randomization studies found that genetically predicted favorable adiposity, HMG-CoA re…
Genetic evidence suggests vitamin D, statins, and dried fruit may lower ovarian cancer risk, but don't change treatment yet.
Digital health tools may ease anxiety and depression in colorectal cancer patients
Digital health tools may ease anxiety and depression in colorectal cancer patients
A meta-analysis of 2018 CRC patients suggests digital health interventions can reduce anxiety and depression while improving quality of life…
A review of 2,018 colorectal cancer patients suggests digital health tools can reduce anxiety and depression and improve quality of life, th…
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Nature-based IVR reduces anxiety and distress in breast cancer patients with low certainty evidence
Nature-based virtual reality may ease anxiety and distress for breast cancer patients
This systematic review and meta-analysis evaluated nature-based immersive virtual reality (IVR) for breast cancer patients. The pooled analy…
A new analysis suggests nature-based virtual reality could help reduce anxiety and distress in breast cancer patients, offering a new tool f…
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma shows TTF-1 expression and Ki-67 less than 10% in reported cases
Thyroid-like cancer in the nose shows unique markers
This case report with literature review describes thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (TL-LGNPPA). The authors sy…
A review of rare thyroid-like cancers in the nose highlights specific markers that help doctors distinguish this condition from other tumors…
FDA Approves Truqap (capivasertib) for HR+/HER2- Advanced Breast Cancer with PIK3CA/AKT1/PTEN Alterations
FDA approves new drug Truqap for certain advanced breast cancers.
The FDA approved Truqap (capivasertib) in combination with fulvestrant for HR-positive, HER2-negative advanced or metastatic breast cancer w…
The FDA approved Truqap (capivasertib) with fulvestrant for adults with HR-positive, HER2-negative advanced breast cancer that has specific …
FDA Approves Decnupaz for Blastic Plasmacytoid Dendritic Cell Neoplasm
FDA approves new drug Decnupaz for rare blood cancer BPDCN
FDA approved Decnupaz (decnupaz) for adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It is a CD123-directed antibo…
The FDA approved Decnupaz for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer. This tar…
FDA Approves Imfinzi (durvalumab) for Resectable NSCLC and Other Indications
FDA approves Imfinzi for multiple cancers including lung and liver.
The FDA approved Imfinzi (durvalumab) for multiple indications including resectable NSCLC, unresectable Stage III NSCLC, LS-SCLC, ES-SCLC, B…
The FDA approved Imfinzi (durvalumab) for several cancers, including lung, liver, bile duct, and stomach cancers. It is used alone or with o…
FDA Approves Columvi (glofitamab) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
FDA approves new drug Columvi for adults with hard-to-treat lymphoma.
The FDA approved Columvi (glofitamab) for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma …
The FDA approved Columvi (glofitamab) for adults with relapsed or refractory diffuse large B-cell lymphoma after two or more treatments. Thi…
FDA Approves Hepzato (melphalan) for Uveal Melanoma with Hepatic Metastases
FDA approves new liver treatment for rare eye cancer that spread to liver.
FDA approved Hepzato (melphalan) as a liver-directed treatment for adult patients with uveal melanoma and unresectable hepatic metastases af…
The FDA approved Hepzato (melphalan) for adults with uveal melanoma that has spread to the liver. It is for patients with limited liver invo…
Physical exercise improves cognitive function in patients with cancer, umbrella review finds
Exercise improves thinking skills in cancer patients, review finds
An umbrella review of 7536 patients with cancer found that physical exercise, typically supervised 12-week aerobic programs at moderate inte…
A new review of 18 studies finds that physical exercise can help cancer patients sharpen their thinking and processing speed.